Systematic review of 2025 RCTs identifies new standards of care across genitourinary cancers
Photo by BoliviaInteligente / Unsplash
Key Takeaway
Consider 2025 RCT evidence for new GU cancer standards; review primary data for specifics.
This systematic review and meta-analysis synthesized evidence from 40 pivotal phase II and III randomized controlled trials in genitourinary oncology presented at ASCO/ESMO 2025 or published in 2025. The population included patients with bladder, kidney, prostate, testicular, and penile cancers. The analysis focused on novel therapeutic strategies, including agents like durvalumab, enfortumab vedotin, pembrolizumab, disitamab vedotin, and toripalimab, compared to various standards of care.
The main finding is that the 2025 evidence establishes multiple new standards of care across these cancers, providing an evidence-based framework for updating clinical guidelines. The review emphasizes trends toward biomarker-driven strategies and the integration of immunotherapy. However, the summary does not report specific numerical results for overall or progression-free survival, such as hazard ratios, absolute numbers, p-values, or confidence intervals.
Safety and tolerability data from the included studies were not extracted or reported in this summary. Key limitations noted include persistent challenges and future research needs in the field. The review performed a risk-of-bias assessment on the included trials. While this analysis consolidates high-level evidence from recent RCTs, clinicians must consult the specific primary publications for detailed efficacy metrics, safety profiles, and precise patient selection criteria to inform practice.
More on Prostate Cancer
Multimodal AI applications in urologic oncology for prostate, bladder, and kidney cancers
Smarter Cancer Care: How AI Is Learning to See the Whole Picture
This narrative review examines multimodal artificial intelligence (AI) applications in urologic oncology for patients with prostate, bladder…
New AI tools combine scans, biopsies, and genes to give clearer answers for prostate, bladder, and kidney cancer patients, though most are s…
Five medications including daptomycin and durvalumab show positive association with drug-induced eosinophilic pneumonia in database analysis.
15,000 Cases Found: Which Drugs Harm Your Lungs?
A retrospective pharmacovigilance investigation analyzed 15,374 cases in FAERS and Vigibase databases to identify drug-induced eosinophilic …
A massive data review reveals which medicines might silently damage your lungs.
Phase 3 RCT Shows Perioperative Enfortumab Vedotin and Pembrolizumab Benefit Muscle-Invasive Bladder Cancer
New Hope for Bladder Cancer Patients Who Can’t Tolerate Standard Chemo
This phase 3 randomized controlled trial enrolled 344 patients with muscle-invasive bladder cancer ineligible for cisplatin-based chemothera…
A new two-drug treatment more than doubles the odds of staying cancer-free for bladder cancer patients who can't handle standard chemo.
Antimicrobial stewardship bundle improved perioperative antibiotic protocol adherence in oncourology surgeries
A Simple Hospital Change Slashed Antibiotic Use Without Harming Patients
A retrospective observational study of 226 patients undergoing prostatectomy or nephrectomy found that implementing an antimicrobial steward…
A focused hospital program slashed antibiotic use by nearly a third while keeping patients safe from dangerous superbugs.
View Original Abstract ↓
BackgroundThe year 2025 has been a transformative moment in GU oncology, with paradigm-shifting clinical trial results presented at major conferences and rapidly published. These developments are recasting therapeutic standards across bladder, kidney, prostate, penile, and testicular cancers through novel mechanisms and refined personalization.ObjectivesThis systematic review aimed to identify, synthesize, and critically evaluate pivotal phase II and III randomized controlled trials presented at ASCO/ESMO 2025 or published in 2025, focusing on innovative therapeutic strategies across GU malignancies.MethodsConducted per PRISMA 2020 guidelines, the review involved exhaustive searches of conference proceedings, PubMed/MEDLINE, and Embase (January-December 2025). Included studies were phase II and III RCTs in GU oncology reporting overall or progression-free survival for novel therapies. Study selection, data extraction, and risk-of-bias assessment using the Cochrane RoB 2 tool were performed.ResultsForty studies met inclusion criteria: bladder cancer (13), kidney cancer (9), prostate cancer (16), testicular cancer (1), and penile cancer (1). Key advances include: (1) In bladder cancer, perioperative durvalumab (NIAGARA) and enfortumab vedotin plus pembrolizumab (KEYNOTE-905/EV-303) set new standards, while HER2-targeted disitamab vedotin plus toripalimab (RC48-C016) improved metastatic survival. Upfront MRI staging (BladderPath) and kidney-sparing approaches (DISTINCT-I) advanced. (2) In kidney cancer, adjuvant durvalumab (RAMPART) and transcriptomic-guided therapy (OPTIC RCC) were established. LenCabo compared post-immunotherapy regimens, and FRUSICA-2 introduced a novel VEGF-TKI/IO combination. (3) In prostate cancer, enzalutamide plus leuprolide improved survival in high-risk biochemical recurrence (EMBARK). Capivasertib plus abiraterone benefited PTEN-deficient metastatic hormone-sensitive disease (CAPItello-281). The PSMAddition trial demonstrated that adding [177Lu]Lu-PSMA-617 to standard therapy significantly improved radiographic PFS in PSMA-positive mHSPC. Docetaxel scheduling was optimized (ARASAFE), and an AI model (STAMPEDE) identified patients for AR inhibitor benefit. Novel agents like saruparib and pasritamig showed promise. (4) In testicular cancer, de-escalated therapy was established for seminoma (SAKK 01/10). (5) In penile cancer, chemotherapy optimization progressed.ConclusionThe 2025 evidence establishes multiple new standards of care across GU cancers, emphasizing biomarker-driven strategies, immunotherapy integration, novel resistance mechanisms, and treatment optimization. This synthesis provides an evidence-based framework for updating guidelines and highlights the move toward more personalized management, while noting persistent challenges and future research needs.
Tirzepatide MTD Demonstrates Cost-Effectiveness Versus Semaglutide MTD in Obesity Simulation Modeling Study
Tirzepatide Saves Money and Health Over Semaglutide
Related in Diabetes & Endocrinology
Review of NHANES data links metformin use to lower mortality and inflammatory markers in type 2 diabetes
Metformin use linked to lower death risk and better inflammation markers in U.S. adults with diabetes
This review of NHANES 2013-2018 data (2,116 adults) found that metformin use was associated with lower all-cause and cardiovascular mortalit…
New analysis of U.S. adults with diabetes suggests metformin use connects to lower death risk and improved inflammation markers, though more…
A 1-month nudge-based dietary intervention increased daily step counts by 1105 steps at 3 months in adults with type 2 diabetes.
Small diet changes might boost steps for a short time in diabetes care
This cluster-randomised controlled trial enrolled 204 adults aged 18-59 years with type 2 diabetes across 12 primary healthcare centres in B…
A simple diet plan helped people with diabetes walk more for three months but the extra steps did not stick in the long run
Mobile app plus group sessions showed feasibility in Malaysian women with gestational diabetes
A new app plus support for diabetes care in Malaysia showed no benefit yet.
This feasibility randomized controlled trial enrolled 60 women with gestational diabetes mellitus in Malaysia. The intervention included mob…
A trial in Malaysia found that a mobile app and group sessions did not improve health outcomes for women with gestational diabetes compared …
Oral Sodium Butyrate Reduces Weight in Overweight Adults Without Diabetes
Oral sodium butyrate helps overweight adults without diabetes lose weight
This 12-week proof-of-concept RCT in 46 overweight adults (23 with type 2 diabetes) found that oral sodium butyrate 1875 mg/day led to great…
A new trial shows oral sodium butyrate helps adults without diabetes lose more weight than a placebo over three months.
From Other Specialties
Systematic review and meta-analysis shows cefotiam reduces postoperative infection in clean surgery
Cefotiam cuts post-surgery infection risk by half compared to no antibiotics
This systematic review and meta-analysis evaluated cefotiam prophylaxis versus no antibiotic prophylaxis or other beta-lactam agents in adul…
A large review found cefotiam lowers infection risk after clean surgery. It works as well as other common antibiotics without causing more s…
Therapeutic Touch Reduces Crying and Improves Sleep in Infants With Colic
Therapeutic touch reduces crying in babies with colic
This randomized controlled trial in 96 infants with colic found that therapeutic touch based on Watson's Human Care Theory significantly red…
A new trial shows gentle therapeutic touch helps babies cry less and sleep better when they have infantile colic.
Mycophenolate mofetil non-inferior to prednisone for first-episode nephrotic syndrome in children
Mycophenolate Mofetil Offers Alternative to Steroids for Nephrotic Syndrome
This phase 3 non-inferiority trial randomized 272 children aged 1-10 years with first-episode steroid-sensitive nephrotic syndrome to mycoph…
A new trial shows mycophenolate mofetil works as well as prednisone for children with nephrotic syndrome, with fewer steroid side effects.
AquOTic water competency intervention improves outcomes in children with autism
Water therapy improves skills for children with autism spectrum disorder
This pre-post cohort study of 37 children with autism ages 5 to 9 found that a 10-week occupational therapy-based water competency intervent…
A water-based occupational therapy program significantly improved performance and satisfaction scores in children with autism spectrum disor…